nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—CYP3A4—Temozolomide—malignant glioma	0.222	1	CbGbCtD
Bicalutamide—Enzalutamide—CYP2B6—malignant glioma	0.0174	1	CrCbGaD
Bicalutamide—Pulmonary fibrosis—Carmustine—malignant glioma	0.012	0.0231	CcSEcCtD
Bicalutamide—Pulmonary fibrosis—Temozolomide—malignant glioma	0.0116	0.0223	CcSEcCtD
Bicalutamide—Lung infiltration—Carmustine—malignant glioma	0.0112	0.0217	CcSEcCtD
Bicalutamide—Cerebral ischaemia—Temozolomide—malignant glioma	0.0105	0.0203	CcSEcCtD
Bicalutamide—Interstitial pneumonia—Temozolomide—malignant glioma	0.0105	0.0203	CcSEcCtD
Bicalutamide—Febrile neutropenia—Carmustine—malignant glioma	0.00875	0.0169	CcSEcCtD
Bicalutamide—Febrile neutropenia—Temozolomide—malignant glioma	0.00846	0.0163	CcSEcCtD
Bicalutamide—Myasthenia—Carmustine—malignant glioma	0.00837	0.0162	CcSEcCtD
Bicalutamide—Cyst—Carmustine—malignant glioma	0.00787	0.0152	CcSEcCtD
Bicalutamide—Interstitial lung disease—Carmustine—malignant glioma	0.00744	0.0144	CcSEcCtD
Bicalutamide—Interstitial lung disease—Temozolomide—malignant glioma	0.00719	0.0139	CcSEcCtD
Bicalutamide—Lung disorder—Temozolomide—malignant glioma	0.00719	0.0139	CcSEcCtD
Bicalutamide—Influenza-like symptoms—Temozolomide—malignant glioma	0.00712	0.0138	CcSEcCtD
Bicalutamide—Hepatotoxicity—Carmustine—malignant glioma	0.00682	0.0132	CcSEcCtD
Bicalutamide—Herpes zoster—Temozolomide—malignant glioma	0.00676	0.013	CcSEcCtD
Bicalutamide—Hepatotoxicity—Temozolomide—malignant glioma	0.00659	0.0127	CcSEcCtD
Bicalutamide—Breast pain—Temozolomide—malignant glioma	0.00583	0.0113	CcSEcCtD
Bicalutamide—Neck pain—Carmustine—malignant glioma	0.00533	0.0103	CcSEcCtD
Bicalutamide—Injection site reaction—Carmustine—malignant glioma	0.00523	0.0101	CcSEcCtD
Bicalutamide—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00509	0.00982	CcSEcCtD
Bicalutamide—Urinary incontinence—Carmustine—malignant glioma	0.00508	0.00981	CcSEcCtD
Bicalutamide—Neuropathy—Carmustine—malignant glioma	0.00494	0.00954	CcSEcCtD
Bicalutamide—Influenza like illness—Temozolomide—malignant glioma	0.00494	0.00954	CcSEcCtD
Bicalutamide—Urinary incontinence—Temozolomide—malignant glioma	0.00491	0.00948	CcSEcCtD
Bicalutamide—Neuropathy—Temozolomide—malignant glioma	0.00478	0.00922	CcSEcCtD
Bicalutamide—Neoplasm—Carmustine—malignant glioma	0.00476	0.00919	CcSEcCtD
Bicalutamide—Gynaecomastia—Carmustine—malignant glioma	0.00471	0.00909	CcSEcCtD
Bicalutamide—Neoplasm—Temozolomide—malignant glioma	0.0046	0.00888	CcSEcCtD
Bicalutamide—Abnormal vision—Carmustine—malignant glioma	0.00459	0.00886	CcSEcCtD
Bicalutamide—Sepsis—Carmustine—malignant glioma	0.00457	0.00882	CcSEcCtD
Bicalutamide—Abnormal vision—Temozolomide—malignant glioma	0.00444	0.00857	CcSEcCtD
Bicalutamide—Thrombophlebitis—Carmustine—malignant glioma	0.00441	0.00852	CcSEcCtD
Bicalutamide—Diabetes mellitus—Carmustine—malignant glioma	0.00439	0.00848	CcSEcCtD
Bicalutamide—Thrombophlebitis—Temozolomide—malignant glioma	0.00427	0.00824	CcSEcCtD
Bicalutamide—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00425	0.0082	CcSEcCtD
Bicalutamide—Hepatic failure—Temozolomide—malignant glioma	0.00411	0.00793	CcSEcCtD
Bicalutamide—Hot flush—Temozolomide—malignant glioma	0.00395	0.00762	CcSEcCtD
Bicalutamide—Menopausal symptoms—Temozolomide—malignant glioma	0.00391	0.00756	CcSEcCtD
Bicalutamide—Face oedema—Carmustine—malignant glioma	0.00369	0.00712	CcSEcCtD
Bicalutamide—Face oedema—Temozolomide—malignant glioma	0.00356	0.00688	CcSEcCtD
Bicalutamide—Liver function test abnormal—Carmustine—malignant glioma	0.00353	0.00681	CcSEcCtD
Bicalutamide—Dehydration—Temozolomide—malignant glioma	0.00343	0.00663	CcSEcCtD
Bicalutamide—Dry skin—Temozolomide—malignant glioma	0.00338	0.00654	CcSEcCtD
Bicalutamide—Muscular weakness—Carmustine—malignant glioma	0.00337	0.00651	CcSEcCtD
Bicalutamide—Breast disorder—Temozolomide—malignant glioma	0.00334	0.00644	CcSEcCtD
Bicalutamide—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.00332	0.00642	CcSEcCtD
Bicalutamide—Dysphagia—Carmustine—malignant glioma	0.0033	0.00638	CcSEcCtD
Bicalutamide—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00326	0.00629	CcSEcCtD
Bicalutamide—Muscular weakness—Temozolomide—malignant glioma	0.00326	0.00629	CcSEcCtD
Bicalutamide—Dysphagia—Temozolomide—malignant glioma	0.00319	0.00616	CcSEcCtD
Bicalutamide—Neutropenia—Carmustine—malignant glioma	0.00309	0.00596	CcSEcCtD
Bicalutamide—Bronchitis—Temozolomide—malignant glioma	0.00307	0.00593	CcSEcCtD
Bicalutamide—Dysuria—Temozolomide—malignant glioma	0.00298	0.00576	CcSEcCtD
Bicalutamide—Neutropenia—Temozolomide—malignant glioma	0.00298	0.00576	CcSEcCtD
Bicalutamide—Hyperglycaemia—Carmustine—malignant glioma	0.00298	0.00575	CcSEcCtD
Bicalutamide—Pneumonia—Carmustine—malignant glioma	0.00296	0.00572	CcSEcCtD
Bicalutamide—Pollakiuria—Temozolomide—malignant glioma	0.00295	0.00569	CcSEcCtD
Bicalutamide—Erectile dysfunction—Temozolomide—malignant glioma	0.00294	0.00568	CcSEcCtD
Bicalutamide—Depression—Carmustine—malignant glioma	0.00294	0.00567	CcSEcCtD
Bicalutamide—Weight increased—Temozolomide—malignant glioma	0.0029	0.00561	CcSEcCtD
Bicalutamide—Weight decreased—Temozolomide—malignant glioma	0.00289	0.00558	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Carmustine—malignant glioma	0.00289	0.00557	CcSEcCtD
Bicalutamide—Hyperglycaemia—Temozolomide—malignant glioma	0.00288	0.00556	CcSEcCtD
Bicalutamide—Urinary tract infection—Carmustine—malignant glioma	0.00286	0.00553	CcSEcCtD
Bicalutamide—Pneumonia—Temozolomide—malignant glioma	0.00286	0.00553	CcSEcCtD
Bicalutamide—Depression—Temozolomide—malignant glioma	0.00284	0.00548	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Temozolomide—malignant glioma	0.00279	0.00539	CcSEcCtD
Bicalutamide—Urinary tract infection—Temozolomide—malignant glioma	0.00277	0.00534	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Temozolomide—malignant glioma	0.00269	0.0052	CcSEcCtD
Bicalutamide—Sinusitis—Temozolomide—malignant glioma	0.00267	0.00515	CcSEcCtD
Bicalutamide—Haemoglobin—Carmustine—malignant glioma	0.00266	0.00513	CcSEcCtD
Bicalutamide—Haemorrhage—Carmustine—malignant glioma	0.00264	0.0051	CcSEcCtD
Bicalutamide—Oedema peripheral—Carmustine—malignant glioma	0.0026	0.00503	CcSEcCtD
Bicalutamide—Haemoglobin—Temozolomide—malignant glioma	0.00257	0.00496	CcSEcCtD
Bicalutamide—Haemorrhage—Temozolomide—malignant glioma	0.00255	0.00493	CcSEcCtD
Bicalutamide—Visual impairment—Carmustine—malignant glioma	0.00255	0.00492	CcSEcCtD
Bicalutamide—Pharyngitis—Temozolomide—malignant glioma	0.00254	0.0049	CcSEcCtD
Bicalutamide—Urinary tract disorder—Temozolomide—malignant glioma	0.00252	0.00487	CcSEcCtD
Bicalutamide—Oedema peripheral—Temozolomide—malignant glioma	0.00252	0.00486	CcSEcCtD
Bicalutamide—Urethral disorder—Temozolomide—malignant glioma	0.0025	0.00483	CcSEcCtD
Bicalutamide—Visual impairment—Temozolomide—malignant glioma	0.00246	0.00475	CcSEcCtD
Bicalutamide—Cardiac disorder—Temozolomide—malignant glioma	0.00237	0.00458	CcSEcCtD
Bicalutamide—Arrhythmia—Carmustine—malignant glioma	0.00236	0.00456	CcSEcCtD
Bicalutamide—Alopecia—Carmustine—malignant glioma	0.00234	0.00451	CcSEcCtD
Bicalutamide—Angiopathy—Temozolomide—malignant glioma	0.00232	0.00448	CcSEcCtD
Bicalutamide—Mental disorder—Carmustine—malignant glioma	0.00232	0.00447	CcSEcCtD
Bicalutamide—Immune system disorder—Temozolomide—malignant glioma	0.00231	0.00446	CcSEcCtD
Bicalutamide—Mediastinal disorder—Temozolomide—malignant glioma	0.0023	0.00445	CcSEcCtD
Bicalutamide—Malnutrition—Carmustine—malignant glioma	0.0023	0.00444	CcSEcCtD
Bicalutamide—Chills—Temozolomide—malignant glioma	0.00229	0.00443	CcSEcCtD
Bicalutamide—Alopecia—Temozolomide—malignant glioma	0.00226	0.00436	CcSEcCtD
Bicalutamide—Mental disorder—Temozolomide—malignant glioma	0.00224	0.00432	CcSEcCtD
Bicalutamide—Back pain—Carmustine—malignant glioma	0.00223	0.0043	CcSEcCtD
Bicalutamide—Malnutrition—Temozolomide—malignant glioma	0.00222	0.00429	CcSEcCtD
Bicalutamide—Back pain—Temozolomide—malignant glioma	0.00215	0.00415	CcSEcCtD
Bicalutamide—Anaemia—Carmustine—malignant glioma	0.00213	0.00411	CcSEcCtD
Bicalutamide—Anaemia—Temozolomide—malignant glioma	0.00206	0.00397	CcSEcCtD
Bicalutamide—Angioedema—Temozolomide—malignant glioma	0.00203	0.00392	CcSEcCtD
Bicalutamide—Hypertension—Carmustine—malignant glioma	0.00199	0.00384	CcSEcCtD
Bicalutamide—Chest pain—Carmustine—malignant glioma	0.00196	0.00378	CcSEcCtD
Bicalutamide—Myalgia—Carmustine—malignant glioma	0.00196	0.00378	CcSEcCtD
Bicalutamide—Anxiety—Carmustine—malignant glioma	0.00195	0.00377	CcSEcCtD
Bicalutamide—Cough—Temozolomide—malignant glioma	0.00194	0.00375	CcSEcCtD
Bicalutamide—Hypertension—Temozolomide—malignant glioma	0.00192	0.00371	CcSEcCtD
Bicalutamide—Confusional state—Carmustine—malignant glioma	0.00189	0.00366	CcSEcCtD
Bicalutamide—Myalgia—Temozolomide—malignant glioma	0.00189	0.00366	CcSEcCtD
Bicalutamide—Anxiety—Temozolomide—malignant glioma	0.00189	0.00364	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00188	0.00363	CcSEcCtD
Bicalutamide—Oedema—Carmustine—malignant glioma	0.00188	0.00363	CcSEcCtD
Bicalutamide—Infection—Carmustine—malignant glioma	0.00187	0.0036	CcSEcCtD
Bicalutamide—Dry mouth—Temozolomide—malignant glioma	0.00185	0.00358	CcSEcCtD
Bicalutamide—Thrombocytopenia—Carmustine—malignant glioma	0.00184	0.00355	CcSEcCtD
Bicalutamide—Confusional state—Temozolomide—malignant glioma	0.00183	0.00353	CcSEcCtD
Bicalutamide—Oedema—Temozolomide—malignant glioma	0.00181	0.0035	CcSEcCtD
Bicalutamide—Infection—Temozolomide—malignant glioma	0.0018	0.00348	CcSEcCtD
Bicalutamide—Anorexia—Carmustine—malignant glioma	0.00179	0.00346	CcSEcCtD
Bicalutamide—Nervous system disorder—Temozolomide—malignant glioma	0.00178	0.00344	CcSEcCtD
Bicalutamide—Thrombocytopenia—Temozolomide—malignant glioma	0.00178	0.00343	CcSEcCtD
Bicalutamide—Skin disorder—Temozolomide—malignant glioma	0.00176	0.0034	CcSEcCtD
Bicalutamide—Hyperhidrosis—Temozolomide—malignant glioma	0.00175	0.00339	CcSEcCtD
Bicalutamide—Anorexia—Temozolomide—malignant glioma	0.00173	0.00334	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00171	0.0033	CcSEcCtD
Bicalutamide—Insomnia—Carmustine—malignant glioma	0.0017	0.00328	CcSEcCtD
Bicalutamide—Paraesthesia—Carmustine—malignant glioma	0.00169	0.00326	CcSEcCtD
Bicalutamide—Dyspnoea—Carmustine—malignant glioma	0.00167	0.00323	CcSEcCtD
Bicalutamide—Somnolence—Carmustine—malignant glioma	0.00167	0.00322	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00165	0.00319	CcSEcCtD
Bicalutamide—Insomnia—Temozolomide—malignant glioma	0.00164	0.00317	CcSEcCtD
Bicalutamide—Decreased appetite—Carmustine—malignant glioma	0.00163	0.00315	CcSEcCtD
Bicalutamide—Paraesthesia—Temozolomide—malignant glioma	0.00163	0.00315	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Carmustine—malignant glioma	0.00162	0.00313	CcSEcCtD
Bicalutamide—Dyspnoea—Temozolomide—malignant glioma	0.00162	0.00312	CcSEcCtD
Bicalutamide—Somnolence—Temozolomide—malignant glioma	0.00161	0.00312	CcSEcCtD
Bicalutamide—Constipation—Carmustine—malignant glioma	0.00161	0.0031	CcSEcCtD
Bicalutamide—Pain—Carmustine—malignant glioma	0.00161	0.0031	CcSEcCtD
Bicalutamide—Dyspepsia—Temozolomide—malignant glioma	0.0016	0.00308	CcSEcCtD
Bicalutamide—Decreased appetite—Temozolomide—malignant glioma	0.00158	0.00305	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00157	0.00303	CcSEcCtD
Bicalutamide—Fatigue—Temozolomide—malignant glioma	0.00156	0.00302	CcSEcCtD
Bicalutamide—Pain—Temozolomide—malignant glioma	0.00155	0.003	CcSEcCtD
Bicalutamide—Constipation—Temozolomide—malignant glioma	0.00155	0.003	CcSEcCtD
Bicalutamide—Feeling abnormal—Carmustine—malignant glioma	0.00155	0.00299	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Carmustine—malignant glioma	0.00154	0.00297	CcSEcCtD
Bicalutamide—Feeling abnormal—Temozolomide—malignant glioma	0.0015	0.00289	CcSEcCtD
Bicalutamide—Abdominal pain—Carmustine—malignant glioma	0.00148	0.00287	CcSEcCtD
Bicalutamide—Body temperature increased—Carmustine—malignant glioma	0.00148	0.00287	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Temozolomide—malignant glioma	0.00148	0.00287	CcSEcCtD
Bicalutamide—Urticaria—Temozolomide—malignant glioma	0.00144	0.00278	CcSEcCtD
Bicalutamide—Abdominal pain—Temozolomide—malignant glioma	0.00143	0.00277	CcSEcCtD
Bicalutamide—Body temperature increased—Temozolomide—malignant glioma	0.00143	0.00277	CcSEcCtD
Bicalutamide—Hypersensitivity—Carmustine—malignant glioma	0.00138	0.00267	CcSEcCtD
Bicalutamide—Asthenia—Carmustine—malignant glioma	0.00135	0.0026	CcSEcCtD
Bicalutamide—Hypersensitivity—Temozolomide—malignant glioma	0.00134	0.00258	CcSEcCtD
Bicalutamide—Asthenia—Temozolomide—malignant glioma	0.0013	0.00251	CcSEcCtD
Bicalutamide—Diarrhoea—Carmustine—malignant glioma	0.00128	0.00248	CcSEcCtD
Bicalutamide—Pruritus—Temozolomide—malignant glioma	0.00128	0.00248	CcSEcCtD
Bicalutamide—Dizziness—Carmustine—malignant glioma	0.00124	0.0024	CcSEcCtD
Bicalutamide—Diarrhoea—Temozolomide—malignant glioma	0.00124	0.0024	CcSEcCtD
Bicalutamide—Dizziness—Temozolomide—malignant glioma	0.0012	0.00232	CcSEcCtD
Bicalutamide—Vomiting—Carmustine—malignant glioma	0.00119	0.00231	CcSEcCtD
Bicalutamide—Rash—Carmustine—malignant glioma	0.00118	0.00229	CcSEcCtD
Bicalutamide—Dermatitis—Carmustine—malignant glioma	0.00118	0.00228	CcSEcCtD
Bicalutamide—Headache—Carmustine—malignant glioma	0.00118	0.00227	CcSEcCtD
Bicalutamide—Vomiting—Temozolomide—malignant glioma	0.00115	0.00223	CcSEcCtD
Bicalutamide—Rash—Temozolomide—malignant glioma	0.00114	0.00221	CcSEcCtD
Bicalutamide—Dermatitis—Temozolomide—malignant glioma	0.00114	0.00221	CcSEcCtD
Bicalutamide—Headache—Temozolomide—malignant glioma	0.00114	0.0022	CcSEcCtD
Bicalutamide—Nausea—Carmustine—malignant glioma	0.00112	0.00215	CcSEcCtD
Bicalutamide—Nausea—Temozolomide—malignant glioma	0.00108	0.00208	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—GJA1—malignant glioma	0.000724	0.00299	CbGpPWpGaD
Bicalutamide—AR—Notch-mediated HES/HEY network—STAT3—malignant glioma	0.000721	0.00298	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—malignant glioma	0.000705	0.00291	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BRCA2—malignant glioma	0.000686	0.00283	CbGpPWpGaD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.000672	0.00277	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—malignant glioma	0.000658	0.00271	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—malignant glioma	0.000649	0.00268	CbGpPWpGaD
Bicalutamide—AR—Nongenotropic Androgen signaling—AKT1—malignant glioma	0.000648	0.00267	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—malignant glioma	0.000646	0.00267	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—HES1—malignant glioma	0.000632	0.00261	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.000618	0.00255	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	0.000615	0.00254	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.000613	0.00253	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—NTRK1—malignant glioma	0.000611	0.00252	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—malignant glioma	0.000586	0.00242	CbGpPWpGaD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	0.00058	0.00239	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—MDM2—malignant glioma	0.000575	0.00237	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—BRCA2—malignant glioma	0.000568	0.00234	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN2B—malignant glioma	0.000563	0.00232	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP2B6—malignant glioma	0.000543	0.00224	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP2B6—malignant glioma	0.000536	0.00221	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.000533	0.0022	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—malignant glioma	0.00053	0.00219	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—HIF1A—malignant glioma	0.000529	0.00218	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PDGFRA—malignant glioma	0.000512	0.00211	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP2B6—malignant glioma	0.0005	0.00206	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP2B6—malignant glioma	0.000495	0.00204	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BAD—malignant glioma	0.000494	0.00204	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP2B6—malignant glioma	0.000493	0.00203	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP2B6—malignant glioma	0.000488	0.00201	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—PTEN—malignant glioma	0.000484	0.002	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP2C18—malignant glioma	0.000471	0.00194	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP2C18—malignant glioma	0.000464	0.00192	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	0.000457	0.00189	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BRAF—malignant glioma	0.00045	0.00186	CbGpPWpGaD
Bicalutamide—CYP3A4—Tryptophan metabolism—CAT—malignant glioma	0.000444	0.00183	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—malignant glioma	0.000438	0.00181	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—malignant glioma	0.000434	0.00179	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP2C18—malignant glioma	0.000433	0.00179	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—STAT3—malignant glioma	0.000433	0.00179	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP2C18—malignant glioma	0.000429	0.00177	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP2C18—malignant glioma	0.000427	0.00176	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP2C18—malignant glioma	0.000423	0.00175	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	0.00041	0.00169	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.000404	0.00167	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	0.000397	0.00164	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—EGFR—malignant glioma	0.000393	0.00162	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	0.000392	0.00162	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BCL2—malignant glioma	0.000383	0.00158	CbGpPWpGaD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	0.000382	0.00158	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—GSTT1—malignant glioma	0.000381	0.00157	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—AKT1—malignant glioma	0.000377	0.00156	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MDM2—malignant glioma	0.000377	0.00156	CbGpPWpGaD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—malignant glioma	0.000367	0.00152	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—NOTCH3—malignant glioma	0.000363	0.0015	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—PTGS1—malignant glioma	0.000357	0.00147	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—GSTT1—malignant glioma	0.00035	0.00145	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—GSTT1—malignant glioma	0.000347	0.00143	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CXCL8—malignant glioma	0.000343	0.00142	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CASP3—malignant glioma	0.000337	0.00139	CbGpPWpGaD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—malignant glioma	0.000335	0.00138	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	0.000334	0.00138	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL1B—malignant glioma	0.000329	0.00136	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CASP3—malignant glioma	0.000329	0.00136	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—PTGS1—malignant glioma	0.000328	0.00135	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP2B6—malignant glioma	0.000327	0.00135	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—NOTCH2—malignant glioma	0.000326	0.00134	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—PTGS1—malignant glioma	0.000325	0.00134	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP2B6—malignant glioma	0.000322	0.00133	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—BCL2—malignant glioma	0.000317	0.00131	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—PTEN—malignant glioma	0.000317	0.00131	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	0.000312	0.00129	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	0.000311	0.00128	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	0.000308	0.00127	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—malignant glioma	0.000301	0.00124	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—malignant glioma	0.000301	0.00124	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—VEGFA—malignant glioma	0.000286	0.00118	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP2C18—malignant glioma	0.000283	0.00117	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—CDKN2B—malignant glioma	0.00028	0.00115	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	0.00028	0.00115	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP2C18—malignant glioma	0.000279	0.00115	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—VEGFA—malignant glioma	0.000279	0.00115	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—AKT1—malignant glioma	0.000279	0.00115	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—RTEL1—malignant glioma	0.000267	0.0011	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—NCOR1—malignant glioma	0.000265	0.00109	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—GSTP1—malignant glioma	0.000264	0.00109	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MYC—malignant glioma	0.000263	0.00109	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	0.000263	0.00108	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—GSTP1—malignant glioma	0.00026	0.00107	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—EGFR—malignant glioma	0.000258	0.00106	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—DNMT3B—malignant glioma	0.000248	0.00102	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—RTEL1—malignant glioma	0.000245	0.00101	CbGpPWpGaD
Bicalutamide—CYP3A4—Tryptophan metabolism—MDM2—malignant glioma	0.000245	0.00101	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—KRAS—malignant glioma	0.000243	0.001	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—RTEL1—malignant glioma	0.000243	0.001	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—GSTP1—malignant glioma	0.000243	0.001	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—HIST1H3B—malignant glioma	0.000241	0.000994	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—GSTP1—malignant glioma	0.000241	0.000993	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—GSTP1—malignant glioma	0.000239	0.000988	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—TNF—malignant glioma	0.000239	0.000986	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—GSTP1—malignant glioma	0.000237	0.000979	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	0.000237	0.000979	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GSTT1—malignant glioma	0.000229	0.000945	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	0.000218	0.0009	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TP53—malignant glioma	0.000216	0.000892	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—PTGS1—malignant glioma	0.000215	0.000885	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	0.000213	0.000881	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	0.000203	0.000839	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	0.000202	0.000832	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—NOTCH1—malignant glioma	0.000201	0.000831	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	0.000191	0.000787	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—PPARG—malignant glioma	0.00019	0.000785	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—H3F3A—malignant glioma	0.000186	0.000768	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	0.000185	0.000764	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	0.000185	0.000761	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—AKT1—malignant glioma	0.000183	0.000754	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	0.000179	0.00074	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NOTCH3—malignant glioma	0.000175	0.000721	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	0.000174	0.000718	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	0.000168	0.000694	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—RTEL1—malignant glioma	0.000161	0.000662	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—GSTP1—malignant glioma	0.000159	0.000655	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NOTCH2—malignant glioma	0.000157	0.000647	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—GSTP1—malignant glioma	0.000157	0.000646	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—COX8A—malignant glioma	0.000153	0.000632	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	0.000151	0.000624	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—COX8A—malignant glioma	0.000141	0.000582	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—COX8A—malignant glioma	0.00014	0.000577	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	0.000137	0.000565	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—CDKN2B—malignant glioma	0.000135	0.000556	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ASMT—malignant glioma	0.00013	0.000538	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NCOR1—malignant glioma	0.000128	0.000527	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	0.000127	0.000526	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	0.000125	0.000516	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—BCAN—malignant glioma	0.000123	0.000506	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ASMT—malignant glioma	0.00012	0.000495	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ASMT—malignant glioma	0.000119	0.00049	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	0.000116	0.000479	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—BCAN—malignant glioma	0.000113	0.000465	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—BCAN—malignant glioma	0.000112	0.000461	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—MYC—malignant glioma	0.000108	0.000447	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—IDH2—malignant glioma	9.88e-05	0.000408	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—NOTCH1—malignant glioma	9.7e-05	0.0004	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	9.32e-05	0.000384	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP2B6—malignant glioma	9.29e-05	0.000383	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—COX8A—malignant glioma	9.22e-05	0.00038	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PPARG—malignant glioma	9.16e-05	0.000378	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—IDH2—malignant glioma	9.09e-05	0.000375	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—IDH2—malignant glioma	9.01e-05	0.000372	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP2B6—malignant glioma	8.54e-05	0.000352	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—IDH1—malignant glioma	8.49e-05	0.00035	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	8.49e-05	0.00035	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP2B6—malignant glioma	8.47e-05	0.000349	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SPHK1—malignant glioma	8.22e-05	0.000339	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP2C18—malignant glioma	8.05e-05	0.000332	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ASMT—malignant glioma	7.84e-05	0.000323	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—IDH1—malignant glioma	7.81e-05	0.000322	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—IDH1—malignant glioma	7.75e-05	0.00032	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	7.59e-05	0.000313	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SPHK1—malignant glioma	7.56e-05	0.000312	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SPHK1—malignant glioma	7.49e-05	0.000309	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP2C18—malignant glioma	7.41e-05	0.000306	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—BCAN—malignant glioma	7.37e-05	0.000304	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP2C18—malignant glioma	7.34e-05	0.000303	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	6.92e-05	0.000286	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	6.92e-05	0.000285	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	6.68e-05	0.000275	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTT1—malignant glioma	6.51e-05	0.000269	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	6.31e-05	0.00026	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTGS1—malignant glioma	6.1e-05	0.000252	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	6.09e-05	0.000251	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	6.08e-05	0.000251	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTT1—malignant glioma	5.99e-05	0.000247	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—IDH2—malignant glioma	5.94e-05	0.000245	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTT1—malignant glioma	5.94e-05	0.000245	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—BCHE—malignant glioma	5.67e-05	0.000234	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTGS1—malignant glioma	5.61e-05	0.000232	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SLC5A5—malignant glioma	5.6e-05	0.000231	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP2B6—malignant glioma	5.59e-05	0.00023	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTGS1—malignant glioma	5.56e-05	0.00023	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	5.54e-05	0.000229	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	5.3e-05	0.000219	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	5.25e-05	0.000217	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—MYC—malignant glioma	5.22e-05	0.000215	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—BCHE—malignant glioma	5.22e-05	0.000215	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—BCHE—malignant glioma	5.17e-05	0.000213	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SLC5A5—malignant glioma	5.15e-05	0.000213	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SLC5A5—malignant glioma	5.11e-05	0.000211	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—IDH1—malignant glioma	5.11e-05	0.000211	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SPHK1—malignant glioma	4.94e-05	0.000204	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP2C18—malignant glioma	4.84e-05	0.0002	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	4.83e-05	0.000199	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	4.79e-05	0.000198	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	4.58e-05	0.000189	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—GSTP1—malignant glioma	4.51e-05	0.000186	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CAT—malignant glioma	4.39e-05	0.000181	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	4.18e-05	0.000172	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—GSTP1—malignant glioma	4.15e-05	0.000171	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NCOR1—malignant glioma	4.15e-05	0.000171	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—GSTP1—malignant glioma	4.12e-05	0.00017	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CAT—malignant glioma	4.04e-05	0.000167	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CAT—malignant glioma	4.01e-05	0.000165	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTT1—malignant glioma	3.92e-05	0.000162	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NCOR1—malignant glioma	3.82e-05	0.000157	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NCOR1—malignant glioma	3.78e-05	0.000156	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTGS1—malignant glioma	3.67e-05	0.000151	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—AKT1—malignant glioma	3.62e-05	0.000149	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—BCHE—malignant glioma	3.41e-05	0.000141	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CAV1—malignant glioma	3.38e-05	0.00014	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SLC5A5—malignant glioma	3.37e-05	0.000139	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.23e-05	0.000133	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CAV1—malignant glioma	3.11e-05	0.000128	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CAV1—malignant glioma	3.08e-05	0.000127	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CG—malignant glioma	3.08e-05	0.000127	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PPARG—malignant glioma	2.97e-05	0.000123	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	2.95e-05	0.000122	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CG—malignant glioma	2.83e-05	0.000117	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CG—malignant glioma	2.81e-05	0.000116	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PPARG—malignant glioma	2.73e-05	0.000113	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—GSTP1—malignant glioma	2.71e-05	0.000112	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PPARG—malignant glioma	2.71e-05	0.000112	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CD—malignant glioma	2.71e-05	0.000112	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CAT—malignant glioma	2.64e-05	0.000109	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NCOR1—malignant glioma	2.49e-05	0.000103	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CD—malignant glioma	2.49e-05	0.000103	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CD—malignant glioma	2.47e-05	0.000102	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CB—malignant glioma	2.36e-05	9.74e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTGS2—malignant glioma	2.34e-05	9.65e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CB—malignant glioma	2.17e-05	8.96e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CB—malignant glioma	2.15e-05	8.88e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTGS2—malignant glioma	2.15e-05	8.87e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTGS2—malignant glioma	2.13e-05	8.8e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTEN—malignant glioma	2.04e-05	8.41e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CAV1—malignant glioma	2.03e-05	8.39e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTEN—malignant glioma	1.88e-05	7.74e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTEN—malignant glioma	1.86e-05	7.67e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CG—malignant glioma	1.85e-05	7.64e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PPARG—malignant glioma	1.79e-05	7.38e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CD—malignant glioma	1.63e-05	6.72e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CA—malignant glioma	1.44e-05	5.94e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CB—malignant glioma	1.42e-05	5.86e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTGS2—malignant glioma	1.41e-05	5.8e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CA—malignant glioma	1.32e-05	5.46e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CA—malignant glioma	1.31e-05	5.41e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTEN—malignant glioma	1.23e-05	5.06e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKT1—malignant glioma	1.18e-05	4.85e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKT1—malignant glioma	1.08e-05	4.46e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKT1—malignant glioma	1.07e-05	4.42e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CA—malignant glioma	8.65e-06	3.57e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKT1—malignant glioma	7.07e-06	2.92e-05	CbGpPWpGaD
